Isoprenaline
| Isoprenaline | |
|---|---|
| Salts [] | |
|---|---|
| Isoprenaline hydrochloride | |
| Isoprenaline disulfate | |
| Isoprenaline hemisulfate | |
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 211.26 g/mol [1] |
| Melting point | 180 [1] |
| Solubility | 5.86e+00 g/L [1] |
| Predicted LogP | -0.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C11H17NO3 |
| IUPAC name | 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol |
| SMILES | CC(C)NCC(C1=CC(=C(C=C1)O)O)O |
| InChI | InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3 |
| InChIKey | JWZZKOKVBUJMES-UHFFFAOYSA-N |
| CAS number | 7683-59-2 |
| UNII | L628TT009W |
| PubChem CID | 3779 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Inhalation: 2–5 min |
| Elimination half-life | Intravenous infusion: 2.5–5 min, Oral: 40 min[3] |
| Duration of action | Inhalation: 0.5–2 hours |
| Metabolism | Methylation (Catechol O-methyltransferase), conjugation (sulfation) |
| Excretion | Urine: 59–107%, Feces: 12–27% |
| Routes of administration | Intravenous, intramuscular, subcutaneous, intracardiac, inhalation, sublingual, rectal[4] |
Isoprenaline (also known as Isopropydrin, Aludrine, Novodrin, Asiprenol, Assiprenol, Bellasthman, Isoprenalin, Respifral, Asmalar or Neodrenal) is a sympathomimetic substance of the catecholamine and phenylethanolamine class.
Chemistry
Salts []
Stereochemistry []
Isoprenaline is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Isoprenaline matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- cardiac therapy (C01)
- cardiac stimulants excl. cardiac glycosides (C01C)
- adrenergic and dopaminergic agents (C01CA)
- (C01CA02)
- isoprenaline (C01CA02)
- respiratory system (R)
- drugs for obstructive airway diseases (R03)
- adrenergics, inhalants (R03A)
- non-selective beta-adrenoreceptor agonists (R03AB)
- isoprenaline (R03AB02)
- adrenergics for systemic use (R03C)
- non-selective beta-adrenoreceptor agonists (R03CB)
- isoprenaline (R03CB01)
MeSH Classification
- adrenergic beta-agonists (M0000494)
- bronchodilator agents (M0002975)
- cardiotonic agents (M0003471)
- sympathomimetics (M0020947)
Mechanism of action []
Isoprenaline is a non-selective beta adrenergic receptor agonist. Agonism of beta-1 and beta-2 adrenergic receptors causes the alpha subunit of G-protein coupled receptors to exchange GMP for GTP, activating them, and allowing the alpha subunit to dissociate from the beta and gamma subunits. Dissociation of the alpha subunit activates adenylate cyclase, converting ATP to cyclic AMP. Cyclic AMP activates protein kinase A (PKA), which phosphorylates cardiac L-type calcium channels such as Ca<sub>v</sub>1.2. These channels depolarize cells by inward active transport of calcium ions. Agonism of beta-1 adrenergic receptors lead to increased strength of contractility, conduction of nerve impulses, speed of relaxation, and rate in the heart. Agonism of beta-2 adrenergic receptors leads to glycogenolysis in the liver, glucagon release from the pancreas, and activation of the renin-angiotensin-aldosterone system. In the alveoli, agonism of beta-2 adrenergic receptors, activates similar pathways to the heart, however the end result is regulation of sodium channels, the cystic fibrosis transmembrane conductance regulator (CFTR), and sodium potassium ATPase. PKA phosphorylates scaffolding proteins and sodium channels, increasing the number of sodium channels on the apical side of alveolar cells and increasing active transport of sodium ions into cells. Agonism of beta-2 adrenergic receptors can also increase chloride ion transport across CFTR. Together, these actions lead to passive transport of water out of the alveoli, and the clearance of alveolar fluid. [1]
Interactions []
Medical side effects []
28 side effects listed on drug labels in SIDER 4.1 (isoproterenol).
- Angina pectoris
- Arrhythmia
- Asthenia
- Bronchospasm
- Dizziness
- Dyspnoea
- Flushing
- Headache
- Cardiac arrest
- Hypertension
- Hypotension
- Nausea
- Nervousness
- Tension
- Pallor
- Palpitations
- Pulmonary oedema
- Convulsion
- Hyperhidrosis
- Tachycardia
- Tremor
- Vertigo
- Tachyarrhythmia
- Ventricular arrhythmia
- Sinus rhythm
- Vision blurred
- Coronary artery insufficiency
- Insomnia
Indications
- Block heart
- Bronchospasm
- Cardiac arrest
- Cardiac failure congestive
- Cardiac fibrillation
- Cardiac output decreased
- Cardiogenic shock
- Electric shock
- Hypoperfusion
- Septic shock
- Ventricular tachycardia
Subjective effects []
Legal status []
- Australia: Isoprenaline is a Schedule 4.
- Other: Isoprenaline is a Rx-only.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3779, Isoprenaline. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3779
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Isoprenaline. UNII: L628TT009W. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/L628TT009W
Isoprenaline: Uses, Interactions, Mechanism of Action. DrugBank Online. 19 February 1948. https://go.drugbank.com/drugs/DB01064
Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 09:59:18 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:59:14 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:59:14 |
| gsrs | ok | 2026-11-20 09:59:18 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015197) | 2026-11-20 09:59:14 |
| kegg | ok | 2026-11-20 09:59:16 |
| pubchem | ok | 2026-11-20 09:59:13 |
| missing (no r/tripreports posts mention it) | 2026-11-20 09:59:14 | |
| sider | ok | 2026-11-20 09:59:14 |
| structure | ok | 2026-11-20 09:59:14 |
| wikipedia | ok | 2026-11-20 09:59:15 |